Calamos Advisors
REGN icon

Calamos Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Calamos Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-215
Closed -$3.45M – 722
2014
Q4 		$3.45M Sell
215
-765
-78% -$301K 0.02% 407
2014
Q3 		$11M Sell
980
-20
-2% -$6.7K 0.07% 246
2014
Q2 		$5.1M Sell
1,000
-988
-50% -$293K 0.03% 332
2014
Q1 		$14.9M Buy
1,988
+130
+7% +$40.1K 0.1% 206
2013
Q4 		$11.7M Sell
1,858
-95
-5% -$27.3K 0.07% 225
2013
Q3 		$19.3M Buy
1,953
+1,523
+354% +$401K 0.12% 182
2013
Q2 		$3.2M Buy
+430
New +$100K 0.02% 343

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Calamos Advisors's REGN Position: Q1 2026 in Review

Calamos Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 11,793 shares worth $9.11M. The position accounts for 0.03% of the portfolio, ranked #424.

Calamos Advisors first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $112M in Q1 2014. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Calamos Advisors held 11,793 shares of Regeneron Pharmaceuticals worth $9.11M as of Q1 2026.
  • Calamos Advisors left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.03% of Calamos Advisors's portfolio in Q1 2026, its #424 holding.
  • Calamos Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's Regeneron Pharmaceuticals position peaked at $112M in Q1 2014.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.